

## GoALS Mission

To accelerate drug discovery and improve clinical outcomes for ALS by delivering a fully integrated, data- and AI-driven platform that bridges academic excellence and industry readiness.

## GoALS at a glance

- Europe's most comprehensive ALS research and clinical platform
- Anchored at UMC Utrecht, connected to TRICALS (largest ALS trial network in Europe)
- 20,000+ patient multi-omics database (genomics, proteomics, biomarkers, imaging, clinical)
- AI-powered tools for disease progression, stratification, and biomarker discovery
- Commercial-ready: pharma partnerships, IP licensing, clinical trial acceleration
- Efficient, fast-track process in place for contract drafting and finalization

## Key Assets

Asset	Description	Collaboration Models
<b>Multi-Omics database</b>	Largest harmonized ALS dataset in EU	Subscriptions, licensing, sponsored research
<b>AI discovery platform</b>	Predictive models for disease progression, treatment response, and drug repurposing opportunities AI-powered models for accurate patient stratification	Data access, co-development, biomarker licensing
<b>Validated Biomarkers</b>	NfL, TDP-43, oxidative stress, EEG, EVs	IP licensing, diagnostic validation, regulatory consulting
<b>Preclinical models and trials</b>	iPSC/organoids, ALS-on-a-chip, TRICALS recruitment	Drug testing, trial optimization services

## Our Unique Edge

- All key capabilities under one roof: data, models, biomarkers, trial execution
- Designed for industry use - not just academic publication
- Already generating revenues through pharma collaborations
- Positioned for scalable, impact-driven commercialization

**We are actively partnering with pharma, biotech, and MedTech companies to bring the next generation of ALS therapies to life - faster and smarter.**



**Let's Connect**

**Rita Machado dos Santos**

Innovation & Valorization Manager, UMC Utrecht



a.r.machadodossantos@umcutrecht.nl